OncoMatch/Colorectal Cancer (CRC)/HER2 (ERBB2)
Colorectal Cancer (CRC)HER2 (ERBB2) Clinical Trials
HER2 amplification or overexpression occurs in approximately 2–3% of metastatic CRC, more commonly in RAS/BRAF wild-type tumors, and predicts resistance to anti-EGFR antibodies while offering an alternative therapeutic target. The trastuzumab plus tucatinib (MOUNTAINEER) regimen received FDA approval for HER2-positive unresectable/metastatic CRC. Trials investigate trastuzumab deruxtecan, bispecific antibodies, and HER2-directed ADCs.
Top recruiting HER2 (ERBB2) Colorectal Cancer (CRC) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Seagen, a wholly owned subsidiary of Pfizer
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
University of Campania Luigi Vanvitelli
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Cancer Research UK
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest